{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T20:47:41Z","timestamp":1791838061033,"version":"4.3.4"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Academy of Consultation-Liaison Psychiatry"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jaclp.2026.09.001","type":"journal-article","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T07:02:44Z","timestamp":1789196564000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Transdermal Buprenorphine in Low-Dose Induction Strategies for Opioid Use Disorder: A Case Report and Systematic Review"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9420-8884","authenticated-orcid":false,"given":"Austin","family":"Pothikamjorn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Li","family":"Suen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin P.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7705-5542","authenticated-orcid":false,"given":"Pooja R.","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaclp.2026.09.001_bib1","article-title":"Drug overdose deaths in the United States, 2003\u20132023","author":"Garnett","year":"2024","journal-title":"NCHS Data Brief"},{"key":"10.1016\/j.jaclp.2026.09.001_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2019.06.039","article-title":"Touchpoints \u2013 opportunities to predict and prevent opioid overdose: a cohort study","volume":"204","author":"Larochelle","year":"2019","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.jaclp.2026.09.001_bib3","article-title":"National U.S. time-trends in opioid use disorder hospitalizations and associated healthcare utilization and mortality","volume":"15","author":"Singh","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jaclp.2026.09.001_bib4","doi-asserted-by":"crossref","DOI":"10.5811\/WESTJEM.58636","article-title":"Disparities in emergency department naloxone and buprenorphine initiation","volume":"24","author":"Papp","year":"2023","journal-title":"West J Emerg Med"},{"key":"10.1016\/j.jaclp.2026.09.001_bib5","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s40122-019-00143-6","article-title":"A narrative pharmacological review of buprenorphine: a unique opioid for the treatment of chronic pain","volume":"9","author":"Gudin","year":"2020","journal-title":"Pain Ther"},{"key":"10.1016\/j.jaclp.2026.09.001_bib6","first-page":"23","article-title":"Suboxone: rationale, science, misconceptions","volume":"18","author":"Velander","year":"2018","journal-title":"Ochsner J"},{"key":"10.1016\/j.jaclp.2026.09.001_bib7","article-title":"Precipitated opioid withdrawal after buprenorphine administration in patients presenting to the emergency department: a case series","volume":"4","author":"Spadaro","year":"2023","journal-title":"J Am Coll Emerg Physicians Open"},{"key":"10.1016\/j.jaclp.2026.09.001_bib8","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.4996","article-title":"Overcoming barriers to prescribing buprenorphine in the emergency department","volume":"3","author":"Kim","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.jaclp.2026.09.001_bib9","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jpainsymman.2022.05.004","article-title":"Barriers to buprenorphine prescribing for opioid use disorder in hospice and palliative care","volume":"64","author":"Ho","year":"2022","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.jaclp.2026.09.001_bib10","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/ADM.0000000000000945","article-title":"Low dose initiation of buprenorphine: a narrative review and practical approach","volume":"16","author":"Cohen","year":"2022","journal-title":"J Addict Med"},{"key":"10.1016\/j.jaclp.2026.09.001_bib12","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.26077","article-title":"Hospital-based methadone and buprenorphine initiation practices by addiction consult services","volume":"8","author":"Cohen","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jaclp.2026.09.001_bib13","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/ajad.13135","article-title":"Microinduction of Buprenorphine\/Naloxone: a review of the literature","volume":"30","author":"Ahmed","year":"2021","journal-title":"Am J Addict"},{"key":"10.1016\/j.jaclp.2026.09.001_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.addbeh.2020.106740","article-title":"Short communication: systematic review on effectiveness of micro-induction approaches to buprenorphine initiation","volume":"114","author":"Moe","year":"2021","journal-title":"Addict Behav"},{"key":"10.1016\/j.jaclp.2026.09.001_bib15","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/phar.2676","article-title":"Buprenorphine initiation strategies for opioid use disorder and pain management: a systematic review","volume":"42","author":"Spreen","year":"2022","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jaclp.2026.09.001_bib16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13722-025-00548-z","article-title":"Initiating buprenorphine to treat opioid use disorder without prerequisite withdrawal: an updated systematic review","volume":"20","author":"Adams","year":"2025","journal-title":"Addict Sci Clin Pract"},{"key":"10.1016\/j.jaclp.2026.09.001_bib17","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jaclp.2025.11.001","article-title":"Transdermal initiation of buprenorphine among hospitalized persons: a retrospective study","volume":"67","author":"Hathaway","year":"2026","journal-title":"J Acad Consult Liaison Psychiatry"},{"issue":"10","key":"10.1016\/j.jaclp.2026.09.001_bib18","first-page":"2127","article-title":"Methodological quality of case series studies: an introduction to the JBI critical appraisal tool","volume":"18","author":"Munn","year":"2019","journal-title":"JBI Evid Synth"},{"key":"10.1016\/j.jaclp.2026.09.001_bib19","doi-asserted-by":"crossref","first-page":"e1872","DOI":"10.1093\/milmed\/usaa068","article-title":"Case report: buprenorphine induction using transdermal buprenorphine in a veteran with opioid use disorder and psychosis, managing precipitated withdrawal","volume":"185","author":"Kinasz","year":"2020","journal-title":"Mil Med"},{"key":"10.1016\/j.jaclp.2026.09.001_bib20","doi-asserted-by":"crossref","first-page":"20","DOI":"10.17161\/kjm.vol17.21229","article-title":"The effectiveness of buprenorphine transdermal patch and low dose sublingual buprenorphine induction to transition to long-acting subcutaneous buprenorphine injection in opioid use disorder in inpatient setting","volume":"17","author":"Gorham","year":"2024","journal-title":"Kans J Med"},{"key":"10.1016\/j.jaclp.2026.09.001_bib21","first-page":"63","article-title":"Successful buprenorphine-naloxone induction after buprenorphine transdermal patch in severe loperamide toxicity requiring transvenous pacing","volume":"19","author":"Dave","year":"2023","journal-title":"J Med Toxicol"},{"key":"10.1016\/j.jaclp.2026.09.001_bib22","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/02024458-201706000-00006","article-title":"Case report: High-dose methadone transition to buprenorphine\/naloxone in an inpatient with a prolonged QT interval","volume":"8","author":"Cortina","year":"2017","journal-title":"Can J Addict"},{"key":"10.1016\/j.jaclp.2026.09.001_bib23","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s42399-022-01222-0","article-title":"Transdermal low-dose buprenorphine induction to transition a patient off a higher-dose methadone regimen: a case report","volume":"4","author":"Braun","year":"2022","journal-title":"SN Compr Clin Med"},{"key":"10.1016\/j.jaclp.2026.09.001_bib24","doi-asserted-by":"crossref","first-page":"e504","DOI":"10.1097\/MJT.0000000000001108","article-title":"Buprenorphine induction without opioid withdrawal: a case series of 15 opioid-dependent inpatients induced on buprenorphine using microdoses of transdermal buprenorphine","volume":"28","author":"Raheemullah","year":"2021","journal-title":"Am J Ther"},{"key":"10.1016\/j.jaclp.2026.09.001_bib25","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13722-024-00479-1","article-title":"Rapid induction of transdermal buprenorphine to subcutaneous extended-release buprenorphine for the treatment of opioid use disorder","volume":"19","author":"Azar","year":"2024","journal-title":"Addict Sci Clin Pract"},{"key":"10.1016\/j.jaclp.2026.09.001_bib26","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/15360288.2023.2222021","article-title":"Buprenorphine inductions via transdermal patches for opioid use disorder in the inpatient setting","volume":"37","author":"Porras","year":"2023","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"10.1016\/j.jaclp.2026.09.001_bib27","article-title":"Adapting low-dose buprenorphine induction to meet patient needs: a pilot study","volume":"5","author":"Karavolis","year":"2022","journal-title":"Drug Alcohol Dependence Rep"},{"key":"10.1016\/j.jaclp.2026.09.001_bib28","first-page":"116","article-title":"Utilizing transdermal buprenorphine for rapid induction of opioid agonist therapy (OAT) in hospitalized patients on either short- or long-acting opioids","volume":"16","author":"Micciche","year":"2020","journal-title":"J Med Toxicol"},{"key":"10.1016\/j.jaclp.2026.09.001_bib29","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/ajad.12964","article-title":"Case series: limited opioid withdrawal with use of transdermal buprenorphine to bridge to sublingual buprenorphine in hospitalized patients","volume":"29","author":"Tang","year":"2020","journal-title":"Am J Addict"},{"key":"10.1016\/j.jaclp.2026.09.001_bib30","first-page":"689","article-title":"Limited opioid withdrawal with utilization of transdermal buprenorphine to bridge to sublingual buprenorphrine\/naloxone: a case series","volume":"55","author":"Leen","year":"2017","journal-title":"Clin Toxicol"},{"key":"10.1016\/j.jaclp.2026.09.001_bib31","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1080\/15563650.2025.2553811","article-title":"Transdermal buprenorphine patch-facilitated induction of sublingual buprenorphine in hospitalized patients receiving full agonist opioids: a retrospective cohort study","volume":"63","author":"Ostrowski","year":"2025","journal-title":"Clin Toxicol"},{"key":"10.1016\/j.jaclp.2026.09.001_bib32","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1080\/15563650.2022.2028802","article-title":"Transdermal buprenorphine for in-hospital transition from full agonist opioids to sublingual buprenorphine: a retrospective observational cohort study","volume":"60","author":"Baumgartner","year":"2022","journal-title":"Clin Toxicol"},{"key":"10.1016\/j.jaclp.2026.09.001_bib33","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13722-026-00657-3","article-title":"24-48 h initiation by transdermal buprenorphine for the treatment of opioid use disorder in the inpatient setting: a retrospective chart review","volume":"21","author":"Azar","year":"2026","journal-title":"Addict Sci Clin Pract"},{"key":"10.1016\/j.jaclp.2026.09.001_bib34","doi-asserted-by":"crossref","first-page":"e271","DOI":"10.1097\/ADM.0000000000000618","article-title":"Rapid transition from methadone to buprenorphine utilizing a micro-dosing protocol in the outpatient Veteran Affairs setting","volume":"14","author":"De Aquino","year":"2020","journal-title":"J Addict Med"},{"key":"10.1016\/j.jaclp.2026.09.001_bib35","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1089\/jpm.2022.0182","article-title":"Exploring the barriers to buprenorphine therapy for cancer-related pain and concurrent opioid use disorder: a case report","volume":"25","author":"Seecof","year":"2022","journal-title":"J Palliat Med"},{"key":"10.1016\/j.jaclp.2026.09.001_bib36","doi-asserted-by":"crossref","first-page":"19.124","DOI":"10.7812\/TPP\/19.124","article-title":"Rapid induction therapy for opioid-use disorder using buprenorphine transdermal patch: a case series","volume":"24","author":"Saal","year":"2020","journal-title":"Permanente J"},{"key":"10.1016\/j.jaclp.2026.09.001_bib37","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/AOG.0000000000004311","article-title":"Buprenorphine patch as a bridge to sublingual treatment of opioid use disorder in pregnancy","volume":"137","author":"Galati","year":"2021","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jaclp.2026.09.001_bib38","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1111\/dar.13826","article-title":"Buprenorphine microdosing regimen using transdermal buprenorphine patches to transition from methadone to buprenorphine","volume":"43","author":"Naren","year":"2024","journal-title":"Drug Alcohol Rev"},{"key":"10.1016\/j.jaclp.2026.09.001_bib39","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/j.1521-0391.2011.00159.x","article-title":"Transdermal buprenorphine to switch patients from higher dose methadone to buprenorphine without severe withdrawal symptoms: transdermal buprenorphine for treatment of opiate withdrawal","volume":"20","author":"Hess","year":"2011","journal-title":"Am J Addict"},{"key":"10.1016\/j.jaclp.2026.09.001_bib40","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/1756-0500-7-264","article-title":"The clinical case report: a review of its merits and limitations","volume":"7","author":"Nissen","year":"2014","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.jaclp.2026.09.001_bib41","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/ADM.0000000000001072","article-title":"48-hour induction of transdermal buprenorphine to sublingual buprenorphine\/naloxone: the IPPAS method","volume":"17","author":"Azar","year":"2023","journal-title":"J Addict Med"},{"key":"10.1016\/j.jaclp.2026.09.001_bib42","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/ADM.0000000000001231","article-title":"48-hour induction of transdermal buprenorphine to extended-release buprenorphine","volume":"18","author":"Azar","year":"2024","journal-title":"J Addict Med"},{"key":"10.1016\/j.jaclp.2026.09.001_bib43","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1080\/02791072.2024.2430616","article-title":"24-Hour induction of transdermal buprenorphine to buprenorphine extended-release","volume":"58","author":"Azar","year":"2026","journal-title":"J Psychoactive Drugs"},{"key":"10.1016\/j.jaclp.2026.09.001_bib44","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/dar.13228","article-title":"Managing opioid withdrawal precipitated by buprenorphine with buprenorphine","volume":"40","author":"Oakley","year":"2021","journal-title":"Drug Alcohol Rev"},{"key":"10.1016\/j.jaclp.2026.09.001_bib45","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s11916-023-01116-3","article-title":"Low-dose initiation of buprenorphine: a narrative review","volume":"27","author":"Edinoff","year":"2023","journal-title":"Curr Pain Headache Rep"},{"key":"10.1016\/j.jaclp.2026.09.001_bib46","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/ADM.0000000000000997","article-title":"Escalation of opioid withdrawal frequency and subsequent AMA rates in hospitalized patients from 2017 to 2020","volume":"16","author":"Horton","year":"2022","journal-title":"J Addict Med"},{"key":"10.1016\/j.jaclp.2026.09.001_bib47","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/jamainternmed.2018.6749","article-title":"Initiating opioid agonist treatment for opioid use disorder in the inpatient setting: a teachable moment","volume":"179","author":"Raheemullah","year":"2019","journal-title":"JAMA Intern Med"}],"container-title":["Journal of the Academy of Consultation-Liaison Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667296026000972?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667296026000972?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T20:05:21Z","timestamp":1791835521000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667296026000972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":46,"alternative-id":["S2667296026000972"],"URL":"https:\/\/doi.org\/10.1016\/j.jaclp.2026.09.001","relation":{},"ISSN":["2667-2960"],"issn-type":[{"value":"2667-2960","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transdermal Buprenorphine in Low-Dose Induction Strategies for Opioid Use Disorder: A Case Report and Systematic Review","name":"articletitle","label":"Article Title"},{"value":"Journal of the Academy of Consultation-Liaison Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaclp.2026.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Academy of Consultation-Liaison Psychiatry. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}